Brexanolone (extended-release injectable aqueous suspension formulation)

缓释注射型brexanolone (BXN) 水悬浮剂

Report date: 2024/10/30 11:01:10

Base Information

Drug NameBrexanolone (extended-release injectable aqueous suspension formulation)
Drug Alias NameBRII-296
ClassificationSmall molecules > Steroids
Mechanisms of ActionGamma-aminobutyric acid A receptor modulators
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsDepressive DisorderDepression, Postpartum
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBrii Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesBrii Biosciences (Shanghai) Co LtdBrii Biosciences Inc
Inactive CompaniesN/A
Active IndicationsDepressive DisorderDepression, Postpartum
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A